Treatment stage What may be common What deserves attention Week 1 Nausea, fullness, reduced appetite, bloating, indigestion, diarrhea, constipation, fatigue Repeated vomiting, severe pain, inability to stay hydrated Weeks 2 to 4 Early symptoms may settle, persist, or fluctuate Symptoms interfering with eating, drinking, or daily function Weeks 5 to 8 Symptoms may reappear after clinician-directed dose escalation A significant return or worsening of gastrointestinal symptoms Months 2 to 3 Some patients tolerate treatment more comfortably
Across the telehealth GLP-1 market as of April 2026, monthly totals typically land between roughly $200 and $700+, with wide variance
Renal GLP-1 resistance, associated with attenuated natriuretic responses to GLP-1 has been observed in subjects with T2D (40, 41)
Many patients experience slower progress after nine to twelve months of therapy, although timing varies depending on adherence, dose optimization, and underlying metabolic conditions
Surgical interventions may be considered for select patients with advanced disease unresponsive to conservative management
A recent study involving 3,390 people taking semaglutide or liraglutide found participants who took high doses of their drug 1.7 mg, 2.0 mg or 2.4 mg of semaglutide, or 3 mg of liraglutide lost more weight after a year compared to people taking lower doses
